• Key drivers behind renewed pharma and biotech interest (e.g., Alzheimer’s approvals, novel mechanisms, better biomarkers)
• Understanding the underlying biology of neurological indications
• How can we get better in our understanding the full picture of the diseases?
Moderator: Preben Bruun-Nyzell, Chief Executive Officer, Neurometa Therapeutics
Panellists:
Bilada Bilican, Senior Director, Applied Stem Cell Sciences, AstraZeneca
Jean-Philippe Courade, Chief Scientific Officer, discoveric bio alpha
Ib Vestergaard Klewe, Senior Director, Lundbeck
Stefan Hauser, Group Leader, DZNE & Hertie Institute for Clinical Brain Research
